Predictors and Prognostic Factors of Heart Failure with Improved Ejection Fraction
Authors:
Open Access
- 8 August 2024
- journal article
- research article
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 25 (8) , 280
Abstract
Background: Heart failure with reduced ejection fraction (HFrEF) patients who have improved ejection fraction have a better prognosis than those with persistently reduced ejection fraction. This study aimed to analyze the predictors for progression of patients with HFrEF to heart failure with improved ejection fraction (HFimpEF), as well as their characteristics and analyze predictors for prognosis. Methods: A retrospective analysis was conducted on 1251 patients with HFrEF at baseline, who also had a second echocardiogram ≥3 months. After left ventricular ejection fraction (LVEF) reassessment, patients were separated into the HFimpEF group (n = 408) and the persistent HFrEF group (n = 611). The primary endpoint was a composite of cardiovascular death or heart failure hospitalization. Results: Multivariate logistic regression showed that without history of alcohol consumption (OR: 0.47, 95% CI: 0.28–0.78), non-New York Heart Association (NYHA) class III–IV (OR: 0.28, 95% CI: 0.15–0.52), without dilated cardiomyopathy (OR: 0.47, 95% CI: 0.26–0.84), concomitant hypertension (OR: 1.53, 95% CI: 1.02–2.29), β-blockers use (OR: 2.29, 95% CI: 1.54–3.43), and lower uric acid (OR: 0.999, 95% CI: 0.997–1.000) could predict LVEF improvement. Kaplan-Meier curves demonstrated that HFimpEF patients had a significantly lower incidence of adverse events than HFrEF patients (log Rank p < 0.001). Multivariate Cox regression found that older age (HR: 1.04, 95% CI: 1.02–1.06), NYHA class III–IV (HR: 2.25, 95% CI: 1.28–3.95), concomitant valvular heart disease (HR: 1.98, 95% CI: 1.01–3.85), and higher creatinine (HR: 1.003, 95% CI: 1.001–1.004) were independent risk factors for the primary endpoint in HFimpEF patients. Conclusions: HFrEF patients without a history of alcohol consumption, non-NYHA class III–IV, without dilated cardiomyopathy, concomitant hypertension, β-blockers use, and lower uric acid were more likely to have LVEF improvement. Although the prognosis of HFimpEF patients was better than that of HFrEF patients, older age, NYHA class III–IV, concomitant valvular heart disease, and higher creatinine were still risk factors for cardiovascular events in HFimpEF patients.Keywords
Funding Information
- National Natural Science Foundation of China (81770255)
This publication has 34 references indexed in Scilit:
- Platelet distribution width predicts left ventricular dysfunction in patients with acute coronary syndromes treated with percutaneous coronary interventionPolish Heart Journal, 2017
- New York Heart Association Functional Class, Qrs Duration, and Survival in Heart Failure with Reduced Ejection Fraction: Implications for Cardiac Resychronization TherapyEuropean Journal of Heart Failure, 2016
- The Diagnosis and Evaluation of Dilated CardiomyopathyJACC, 2016
- Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failureHeart and Vessels, 2014
- Long-Term Functional and Clinical Follow-Up of Patients With Heart Failure With Recovered Left Ventricular Ejection Fraction After β-Blocker TherapyCirculation: Heart Failure, 2014
- Cardiorenal SyndromeCirculation, 2010
- Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients With Systolic Chronic Heart Failure Receiving Beta-BlockersThe American Journal of Cardiology, 2008
- Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failureInternational Journal of Cardiology, 2007
- Renal Impairment and Outcomes in Heart FailureJACC, 2006
- Frequency, prognosis and predictors of improvement of systolic left ventricular function in patients with ‘classical’ clinical diagnosis of idiopathic dilated cardiomyopathyEuropean Journal of Heart Failure, 2001